ClinicalTrials.gg
Not yet recruitingNCT07843290Updated Sep 30, 2026

A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis

A Phase 2 interventional study of JYP0066 4% topical cream and 3% JYP0066 topical cream in Atopic Dermatitis (AD), sponsored by Guangzhou JOYO Pharma Co., Ltd. Not yet recruiting. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Guangzhou JOYO Pharma Co., Ltd · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Study summary

This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults. The study will check whether JYP0066 cream can reduce eczema signs and symptoms such as redness, itching, dryness, and skin thickening, and whether it is safe and well tolerated.

Participants will be randomly assigned to one of four groups: they will apply either 4%, 3%, or 2% JYP0066 cream, or a matching placebo cream, to eczema-affected skin twice a day for 8 weeks. All creams will look the same. This helps the study compare which concentration works best and how safe each one is.

02

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

03

In context

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

This study's planned enrollment of 160 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Guangzhou JOYO Pharma Co., Ltd is the lead sponsor of 14 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is ≥12 and ≤75 years of age at the time of signing ; male or female.

Note: Participants who are ≥12 and \<18 years of age at screening and baseline will be classified as adolescents throughout the study.

Body weight ≥40 kg. Meets Williams diagnostic criteria for atopic dermatitis (AD) at screening and baseline, with AD onset at least 6 months before screening.

Williams criteria - Major criterion: itchy skin. Minor criteria: (a) history of flexural dermatitis (elbow/antecubital, popliteal, anterior ankle, neck; in children \<10 y, cheek rash); (b) history of asthma or allergic rhinitis (or atopic disease in first-degree relatives for children \<4 y); (c) generalized dry skin in recent years; (d) flexural eczema (in children \<4 y: cheek/forehead/extensor eczema); (e) onset before age 2 (for patients ≥4 y). Diagnosis = major criterion + ≥3 minor criteria.

vIGA-AD score of 2 (mild) or 3 (moderate) at both screening and baseline. Total AD lesion area of 3%-20% body surface area (BSA) at screening and baseline.

Note: Lesions on scalp, face, and genital area are excluded from BSA calculation at screening and baseline.

Females of must have a negative serum pregnancy test at screening. All participants of childbearing potential (and their partners) must agree to use highly effective from informed consent through 1 month after last study drug administration and must not donate sperm/ova during this period.

Note: Applies also to post-menarchal female adolescents and post-semenarche male adolescents.

Adults: able to understand the purpose and procedures of the study, voluntarily provide written informed consent, and comply with visits/requirements. Adolescents: participant and parent/legal guardian (as applicable) voluntarily provide written informed consent/assent and can communicate with investigator and attend scheduled visits.

Exclusion criteria

Exclusion Criteria:

  • Presence of other skin diseases or skin infections that may interfere with AD assessment at screening/baseline, or large tattoos, birthmarks, or scars over AD lesions at screening/baseline.

Unstable AD, or continuously requiring potent topical to control signs/symptoms.

AD lesions located only or mainly on hands, feet, scalp, face, or genitals with no history of classic flexural involvement.

Known/suspected allergy to any component of study cream or its vehicle, or moderate-to-severe allergic disease at IC signing (e.g., food/drug/detergent allergy; AD-related allergy allowed); or history of moderate-to-severe allergic disease.

Use of any of the following prior to study drug:

Any systemic or topical JAK inhibitor before study entry; Biologics affecting AD (e.g., anti-IL-4, IL-5, IL-12/23, IL-13, IL-31, CD20, TNF-α, IgE) within 12 weeks or 5 half-lives (whichever longer) before study drug; Systemic /immunomodulators (cyclosporine, MTX, azathioprine, MMF), oral/systemic corticosteroids, PDE4 inhibitors within 4 weeks or 5 half-lives (whichever longer); Systemic herbal/Chinese medicine for AD or other -inflammatory diseases within 4 weeks; Phototherapy (NBUVB, UVB, UVA1, PUVA), tanning bed, or other light-emitting device within 4 weeks; Any topical AD treatment (except non-medicated emollient) or antihistamines within 1 week (stable-dose antihistamine before screening allowed); Participation in another clinical trial within 4 weeks or 5 half-lives of product (whichever longer); Any vaccination within 4 weeks, BCG within 1 year, or planned live/attenuated vaccine during study; Long-acting anticoagulants (warfarin, dabigatran) within 4 weeks or need for continuous anticoagulation (aspirin ≤100 mg/day allowed); Strong inhibitors/inducers (rifampin, fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole, nefazodone) within 2 weeks or 5 half-lives; Allergen-specific immunotherapy within 6 months. Major surgical procedure within 12 weeks before screening. Serious infectious disease within 6 months; history of zoster or disseminated zoster; any infection requiring antibiotics within 2 weeks before screening; or active acute/chronic/local infection at screening; or infection judged by investigator likely to worsen with participation.

Active tuberculosis, untreated latent TB, or incompletely cured TB (by history, symptoms, labs, IGRA, imaging).

Conditions negatively affecting immune response (e.g., organ transplant), or known immunodeficiency (acquired, genetic, or drug-induced).

Class III/IV heart failure; unstable angina; stroke/; MI; CABG/PCI history; uncontrolled hypertension (SBP >160 or DBP >100 mmHg); hypotension (SBP \<90 or DBP \<60); electrolyte disorder; or other unstable disease affecting safety.

History of thromboembolic event (DVT, pulmonary embolism, CVA) or known genetic hypercoagulable state.

Clinically relevant severe pulmonary disease (e.g., pulmonary hypertension, acute exacerbation, pneumothorax).

Severe GI disease (peptic ulcer, obstruction) or condition affecting drug absorption (e.g., gastrectomy).

Severe hematologic disease (moderate/severe anemia, proliferative bone marrow disease, thrombocytopenia, hemoglobinopathy), severe coagulation abnormality, or high thrombotic risk.

Malignant tumor or lymphoproliferative disease within past 10 years, except adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia.

Screening 12-lead with prolonged (>450 ms male, >470 ms female), family history of long QT, or chronic use of QT-prolonging drugs.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    4% JYP0066 topical cream - applied twice daily (BID) to affected skin areas for 8 weeks

    Drug: JYP0066 4% topical cream

  • Experimental
    3% JYP0066 topical cream - applied twice daily (BID) for 8 weeks

    Drug: 3% JYP0066 topical cream

  • Experimental
    2% JYP0066 topical cream - applied twice daily (BID) for 8 weeks

    Drug: 2% JYP0066 topical cream

  • Placebo comparator
    Matching placebo cream (vehicle, no active ingredient) - applied twice daily (BID) for 8 weeks

    Drug: Matching placebo cream (vehicle, no active ingredient)

Interventions

  • DrugJYP0066 4% topical cream

    applied twice daily (BID) to affected skin areas for 8 weeks

  • Drug3% JYP0066 topical cream

    applied twice daily (BID) for 8 weeks

  • Drug2% JYP0066 topical cream

    applied twice daily (BID) for 8 weeks

  • DrugMatching placebo cream (vehicle, no active ingredient)

    applied twice daily (BID) for 8 weeks

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in EASI score at Week 8

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Proportion of participants achieving EASI 50/75/90 at Weeks 1, 2, 4, and 8

    Time frame: Weeks 1, 2, 4, 8

  2. Percent change from baseline in EASI score at Weeks 1, 2, and 4

    Time frame: Weeks 1, 2, 4

  3. Proportion of participants with vIGA-AD response at Weeks 1, 2, 4, 8

    Time frame: Weeks 1, 2, 4, 8

  4. Proportion of participants with vIGA-AD score 0/1 at Weeks 1, 2, 4, 8

    Time frame: Weeks 1, 2, 4, 8

  5. Proportion of participants with ≥2-point improvement in vIGA-AD from baseline at Weeks 1, 2, 4, 8

    Time frame: Weeks 1, 2, 4, 8

07

Study locations

No study locations are listed for this record.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Sep 28, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Phase II TrialA Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
Sep 30, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Sep 30, 2026
    Title Phase II TrialA Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07843290
Lead sponsor
Guangzhou JOYO Pharma Co., Ltd
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion